STOCKHOLM – Stockholm’s transition to a 21st century location for discovery science and drug development is under way in earnest, as two separate research partnerships between Astrazeneca plc and the Karolinska Institute start to gather momentum, while a preclinical drug development “toolbox,” aimed at academic researchers, will put out a call for its first projects in the coming months.